Malignant hyperthermia

European Journal of Anaesthesiology

Volumn 18, Issue 10, 2001, Pages 632-652

  Wappler, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Alkaloids, ryanodine; Anaesthesia and analgesia, preoperative complications, malignant hyperthermia; Anaesthetics, inhalation, halothane; Enzyme inhibitors, phosphodiesterase inhibitors, caffeine; Muscle relaxants, central, dantrolene; Neuroleptic malignant syndrome; Pathological processes, postoperative complications, malignant hyperthermia, diagnosis, epidemiology; Xanthines, caffeine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BORATE SODIUM; CAFFEINE; CALCIUM; CARBON DIOXIDE; CRESOL; DANTROLENE; DESFLURANE; ENFLURANE; ETOMIDATE; HALOTHANE; INHALATION ANESTHETIC AGENT; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NEUROMUSCULAR DEPOLARIZING AGENT; NITROUS OXIDE; OPIATE; OXYGEN; PHENOTHIAZINE DERIVATIVE; PROPOFOL; RITANSERIN; RYANODINE; RYANODINE RECEPTOR; SEDATIVE AGENT; SEROTONIN 2 ANTAGONIST; SEVOFLURANE; SUXAMETHONIUM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VOLATILE AGENT;

AUTOSOMAL DOMINANT INHERITANCE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; HUMAN; HYPERMETABOLISM; INCIDENCE; MALIGNANT HYPERTHERMIA; MUSCLE FIBRIL; MUTATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROMUSCULAR DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SARCOPLASMIC RETICULUM; SEROTONINERGIC SYSTEM; SKELETAL MUSCLE; STRESS; TRISMUS;

ANESTHESIA; ANIMALS; HUMANS; MALIGNANT HYPERTHERMIA; MUSCULAR DISEASES; SECOND MESSENGER SYSTEMS; SEROTONIN; STRESS, PSYCHOLOGICAL; TEMPERATURE;

EID: 0034800480     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2346.2001.00888.x     Document Type: Review

References (195)

1. Malignant hyperthermia
2. Heat-stroke as a post-operative complication
3. Heat-stroke as a post-operative complication
4. Postoperative heatstroke
5. Le syndrom paleur et hyperthémie chez les nourissons opéres
6. Anaesthetic deaths in a family
7. Anaesthetic deaths in a family
8. Metabolic error of muscle metabolism after recovery from malignant hyperthermia
9. Halothane-induced muscle contracture as a cause of hyperpyrexia
10. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility
11. Standardization of the caffeine halothane muscle contracture test
12. Dantrolene in human malignant hyperthermia: A multicenter study
13. An update on the malignant hyperthermia syndrome
14. The genetics of malignant hyperthermia
15. Investigation of malignant hyperthermia susceptibility in Denmark
16. 2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs
17. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia
18. 2+ release by skeletal muscle sarcoplasmic reticulum
19. Functional subunit structure of voltage-gated calcium channels
20. Complex pharmacology of malignant hyperthermia
21. Purification and reconstitution of the calcium release channel from skeletal muscle
22. Three-dimensional architecture of the calcium channel/foot structure of sarcoplasmic reticulum
23. Intramembrane charge movement restored in dysgenic muscle by injection of dihydropyridine receptor DNAs
24. 2+ regulation defects
25. 2+ channel activity
26. Biochemical characterization of ultrastructural localization of a major junctional sarcoplasmic reticulum glycoprotein (triadin)
27. Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle
28. 2+ release channel
29. Structure and function of ryanodine receptors
30. Malignant hyperthermia
31. 2+ ions in excitation-contraction coupling of skeletal muscle fibres
32. 2+ release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles
33. Effects of the halothane-sensivity gene on sarcoplasmic reticulum function
34. 2+ release channels in malignant hyperthermic skeletal muscle
35. Abnormal ryanodine receptor channels in malignant hyperthermia
36. ++ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle
37. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia
38. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia
39. Inositol 1,4,5,-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine
40. Inositol 1,4,5-trisphosphate metabolism in red blood cells from individuals susceptible to malignant hyperpyrexia
41. Inositol-1,4,5-trisphophate and malignant hyperthermia
42. Possible involvement of inositol-lipid metabolism in malignant hyperthermia
43. Biochemical changes in malignant hyperthermia susceptible swine: Cyclic AMP, inositol phosphates, alpha 1, beta 1- and beta 2-adrenoceptors in skeletal and cardiac muscle
44. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia
45. Opening of dihydropyridine calcium channels in skeletal muscle membranes by inositol trisphosphate
46. Inositol trisphosphate and calcium signalling
47. 2+ release
48. 400
49. Putative receptor for inositol 1,4,5-trisphosphate similar to ryanodine receptor
50. Hypersensitive response of malignant hyperthermia-susceptible skeletal muscle to inositol 1,4,5-trisphosphate induced release of calcium
51. Influence of phenoxybenzamine and propanolol on blood serotonin and pH, plasma cortisol and M. longissimus pH and color in swine
52. Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs
53. Inhibition by serotonin of amino acid release and protein degradation in skeletal muscle
54. Serotonergic and adrenergic regulation of skeletal muscle metabolism in the rat. II. The use of [125] iodolysergic acid diethylamide and [125] iodopindolol as probes of sarcolemmal receptor function and specificity
55. 2 receptors induces malignant hyperthermia
56. Ketanserin and malignant hyperthermia in pigs
57. 2A receptor antagonists in halothane-induced porcine malignant hyperthermia
58. 2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients
59. 2 receptor agonist DOI on skeletal muscles from malignant hyperthermia susceptible patients
60. Attenuation of serotonin-induced contractures in skeletal muscles from malignant hyperthermia susceptible patients with dantrolene
61. Cardiovascular and metabolic responses to anesthetic-induced malignant hyperthermia in swine
62. Abnormal action potential responses to halothane in heart muscle isolated from malignant hyperthermia-susceptible pigs
63. Effects of beta- and alpha-adrenergic agonists, adenosine and carbachol on heart muscle isolated from malignant hyperthermia susceptible swine
64. Alterations in brain electrical activity may indicate the onset of malignant hyperthermia in swine
65. Improvement of brain electrical activity during treatment of porcine malignant hyperthermia with dantrolene
66. Cerebral metabolism during porcine malignant hyperthermia
67. 2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia
68. Malignant hyperthermia triggered by heating in anaesthetized pigs
69. Prior hypothermia attenuates malignant hyperthermia in susceptible swine
70. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility
71. Masseteric muscle spasm as a normal response to suxamethonium
72. Masseter spasm with anesthesia. Incidence and implications
73. Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine
74. Jaw relaxation after a halothane/succinylcholine sequence in children
75. Masseter spasm and elevated creatine kinase after intravenous induction in a child
76. Masseter muscle rigidity and malignant hyperthermia susceptibility
77. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis
78. The effects of succinylcholine on mouth opening
79. Increased masticatory muscle stiffness during limb muscle flaccidity associated with succinylcholine administration
80. 1306-to-alanine mutation in the adult muscle sodium channel alpha-subunit gene
81. Halothane induces calcium release from human skinned masseter muscle fibers
82. Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment
83. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum
84. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications
85. Azumolene reverses episodes of malignant hyperthermia in susceptible swine
86. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: An investigation in rats, dogs, and swine
87. The effects of calcium channel blocking drugs on halothane initiation of malignant hyperthermia in MHS swine and on the established syndrome
88. Hyperkalemia, verapamil, and dantrolene
89. 2, calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine
90. Malignant Hyperthermia: A human stress syndrome?
91. Combined anesthetic- and stress-induced malignant hyperthermia in two offspring of malignant hyperthermic-susceptible parents
92. Evidence for susceptibility to malignant hyperthermia in patients with stress-induced rhabdomyolysis
93. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy
94. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia
95. Femoral block with mepivacaine for muscle biopsy in malignant hyperthermia patients
96. Sevoflurane triggers malignant hyperthermia in swine
97. Desflurane is a trigger of malignant hyperthermia in susceptible swine
98. Malignant hyperthermia during sevoflurane administration
99. Malignant hyperthermia involving the administration of desflurane
100. Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine
101. Effects of droperidol, haloperidol and ketamine on halothane, suc-cinylcholine and caffeine contractures: Implications for malignant hyperthermia
102. Suxamethonium chloride and malignant hyperpyrexia
103. 2+ channel
104. 4-Chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations
105. 4-Chloro-m-cresol is a trigger of malignant hyperthermia in susceptible swine
106. Unusual reaction to suxamethonium chloride
107. Porcine malignant hyperthermia (Porcine stress syndrome)
108. Human malignant hyperthermia: Awake episodes and correction by dantrolene
109. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe excercise-induced myolysis
110. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing
111. In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis
112. Role of sympathetic activity in porcine malignant hyperthermia
113. Failure of norepinephrine to initiate porcine malignant hyperthermia
114. Norepinephrine does not potentiate porcine malignant hyperthermia
115. A clinical grading scale to predict malignant hyperthermia susceptibility
116. Evaluierung von maligne-hyperthermie-episoden mit der clinical grading scale
117. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects
118. The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry of MHAUS
119. False-negative results with the muscle caffeine halothane contracture testing for malignant hyperthermia
120. Malignant hyperthermia - Diagnostic dilemma: False-negative contracture responses with halothane and caffeine alone
121. 2+ release channel
122. Ryanodine contracture: A potentially specific in vitro diagnostic test for malignant hyperthermia
123. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man
124. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles
125. Malignant hyperthermia (MH) diagnostics: A comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle
126. The multi centre evaluation of ryanodine contracture testing in malignant hyperthermia
127. 2+ release
128. 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor
129. 4-Chloro-m-cresol: A specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle
130. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility
131. In vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility: A European multicentre study
132. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations
133. Erythrocyte osmotic fragility in hyperthermia-susceptible swine
134. Platelet model for halothane-induced effects on nucleotide metabolism applied to malignant hyperthermia
135. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia
136. Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia susceptible patients
137. 2+ in blood cells in malignant hyperthermia
138. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings following in vitro exposure to halothane, caffeine and ryanodine
139. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors
140. Electrodiagnostic tests in the detection of malignant hyperthermia
141. Detection of malignant hyperthermia susceptibility using a spin label technique on red blood cells
142. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility
143. Malignant hyperthermia: Relationship to other diseases
144. Malignant hyperthermia: Relation to other diseases
145. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies
146. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2
147. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q
148. Genetics and pathogenesis of malignant hyperthermia
149. Close linkage established between the HAL locus for halothane sensitivity and the PHI (phosphohexose isomerase) locus in pigs of the Danish landrace breed
150. Porcine malignant hyperthermia carrier detection and chromosomal assignment using a linked probe
151. Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11-q21 segment of chromosome 6
152. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum
153. The human ryanodine receptor gene: Its mapping to 19q13.1, placement in a chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy
154. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia
155. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia
156. Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families
157. A substitution of cysteine for argenine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia
158. Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia
159. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: Frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response
160. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHSI region on chromosome 19q12-13.2, comprising the C1840T transition in the RYRI gene
161. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene and individuals with malignant hyperthermia
162. High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families
163. A mutation in the ryanodine receptor gene associated with central core disease
164. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia
165. Malignant hyperthermia susceptibility is associated with a mutation of the alpha1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle
166. Mutation screening of the RYR1 gene in malignant hyperthermia: Detection of a novel Tyr to Ser mutation in a pedigree with associated central cores
167. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis
168. Detection of a novel mutation in the ryanodine receptor gene in malignant hyperthermia: Implications for diagnosis and heterogeneity studies
169. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families
170. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees
171. A calcium channel mutation causing hypokalemic periodic paralysis
172. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia
173. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1
174. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia
175. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: Correlation of the IVCT response with the affected and unaffected haplotypes
176. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35 Arg in a large kindred
177. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees
178. 2+ release channel function and severe central core disease
179. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia
180. Identification of a novel ryanodine-receptor gene (RYR1) in malignant hyperthermia: Genotype-phenotype correlation
181. Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families
182. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test
183. F. III-IV loop of cardiac L-type calcium channel contributes to fast inactivation as implied by a naturally occuring disease-causing mutation
184. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family
185. In vitro contracture tests in patients with various neuromuscular diseases
186. Viability criterion of muscle bundles used in the in vitro con-tracture test in patients with neuromuscular diseases
187. Malignant hyperthermia and myotonia congenita
188. Central core disease and malignant hyperthermia syndrome
189. Malignant hyperthermia and central core disease in a child with congenital dislocating hips
190. Central/minicore disease or histological pattern, and MH susceptibility
191. Anesthesia-related complications in children with Duchenne muscular dystrophy
192. Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease
193. Assignment of the gene for central core disease to chromosome 19
194. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families
195. The neuroleptic malignant syndrome: Agent and host interaction